RESUMEN
Fibroblast growth factors (FGFs) are a family of proteins possessing paracrine, autocrine, or endocrine functions in a variety of biological processes, including embryonic development, angiogenesis, tissue homeostasis, wound repair, and cancer. Canonical FGFs bind and activate tyrosine kinase FGF receptors (FGFRs), triggering intracellular signaling cascades that mediate their biological activity. Experimental evidence indicates that FGFs play a complex role in the physiopathology of the prostate gland that ranges from essential functions during embryonic development to modulation of neoplastic transformation. The use of ligand- and receptor-deleted mouse models has highlighted the requirement for FGF signaling in the normal development of the prostate gland. In adult prostate, the maintenance of a functional FGF/FGFR signaling axis is critical for organ homeostasis and function, as its disruption leads to prostate hyperplasia and may contribute to cancer progression and metastatic dissemination. Dissection of the molecular landscape modulated by the FGF family will facilitate ongoing translational efforts directed toward prostate cancer therapy.
Asunto(s)
Factores de Crecimiento de Fibroblastos/fisiología , Próstata/fisiología , Próstata/fisiopatología , Enfermedades de la Próstata/fisiopatología , Neoplasias de la Próstata/fisiopatología , Receptores de Factores de Crecimiento de Fibroblastos/fisiología , Animales , Humanos , Péptidos y Proteínas de Señalización Intercelular/fisiología , Masculino , Próstata/crecimiento & desarrolloRESUMEN
INTRODUCTION: Many studies have looked at global changes in the International Prostate Symptom Score (IPSS) following PAE; however, no studies have examined the breakdown between storage and voiding symptoms. We aimed to explore the extent to which PAE improves storage symptoms in relation to voiding symptoms. METHOD: This single-center, prospective cohort study recruited consecutive patients undergoing PAE from June 2012 to June 2016. The IPSS breakdown was recorded pre-PAE, at 3 months and 12 months post-PAE. Planned statistical analysis included the paired t test. RESULTS: A total of 43 patients were recruited (mean age 64.72 ± 6.27, prostate volume 88.65 ± 37.23 cm3, IPSS 23.02 ± 5.84, QoL 4.98 ± 1.01, PSA 4.2 ± 2.8). Storage symptoms were more frequently the most severe symptom (58.1%). Voiding score (13.35-5.39, p < 0.001) and storage score (9.67-5.08, p < 0.001) both improved; however, voiding improved to a greater extent (1.9 vs. 1.5 mean per question, p = 0.023). PAE was most consistent when improving storage symptoms ('Urgency' improved in 86% patients, 'Frequency' and 'Nocturia' 77%). CONCLUSION: Storage symptoms are a significant problem for patients with benign prostatic obstruction. PAE is an effective treatment for both storage and voiding symptoms. More research is needed to evaluate how this compares with surgical techniques.
Asunto(s)
Embolización Terapéutica/métodos , Próstata/irrigación sanguínea , Enfermedades de la Próstata/complicaciones , Enfermedades de la Próstata/terapia , Trastornos Urinarios/complicaciones , Trastornos Urinarios/terapia , Arterias , Estudios de Cohortes , Humanos , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Enfermedades de la Próstata/fisiopatología , Resultado del Tratamiento , Trastornos Urinarios/fisiopatologíaRESUMEN
The aim of this study was to determine whether, after 8 days of water-only fasting, there are changes in the efficiency of the lower urinary tract, the concentration of sex hormones, and the symptoms of prostate diseases in a group of middle-aged men (n = 14). For this purpose, before and after 8 days of water-only fasting (subjects drank ad libitum moderately mineralized water), and the following somatic and blood concentration measurements were made: total prostate specific antigen (PSA-T), free prostate specific antigen (PSA-F), follicle stimulating hormone (FSH), luteotropic hormone (LH), prolactin (Pr), total testosterone (T-T), free testosterone (T-F), dehydroepiandrosterone (DHEA), sex hormone globulin binding (SHGB), total cholesterol (Ch-T), ß-hydroxybutyrate (ß-HB). In addition, prostate volume (PV), volume of each testis (TV), total volume of both testes (TTV), maximal urinary flow rate (Qmax), and International Prostate Symptom Score (IPSS) values were determined. The results showed that after 8 days of water-only fasting, Qmax and IPSS improved but PV and TTV decreased significantly. There was also a decrease in blood levels of PSA-T, FSH, P, T-T, T-F, and DHEA, but SHGB concentration increased significantly. These results indicate that 8 days of water-only fasting improved lower urinary tract functions without negative health effects.
Asunto(s)
Ayuno , Aguas Minerales/administración & dosificación , Testículo , Sistema Urinario , Adulto , Colesterol/sangre , Hormonas Esteroides Gonadales/sangre , Humanos , Hidroxibutiratos/sangre , Masculino , Persona de Mediana Edad , Tamaño de los Órganos , Enfermedades de la Próstata/sangre , Enfermedades de la Próstata/patología , Enfermedades de la Próstata/fisiopatología , Enfermedades de la Próstata/terapia , Globulina de Unión a Hormona Sexual/metabolismo , Testículo/patología , Testículo/fisiopatología , Sistema Urinario/patología , Sistema Urinario/fisiopatologíaRESUMEN
A 64-year-old man was referred to our urology outpatient clinic with lower urinary tract symptoms (LUTS). During rectal examination a smooth nodule was identified. MRI-images showed a prostatic cyst, originating from the utriculus. An utriculus cyst is a relatively rare finding and originates from a persistent remnant of the Müllerian duct.
Asunto(s)
Quistes , Síntomas del Sistema Urinario Inferior , Próstata , Enfermedades de la Próstata , Neoplasias de la Próstata/diagnóstico , Diagnóstico Diferencial , Humanos , Síntomas del Sistema Urinario Inferior/diagnóstico , Síntomas del Sistema Urinario Inferior/etiología , Imagen por Resonancia Magnética/métodos , Masculino , Persona de Mediana Edad , Próstata/diagnóstico por imagen , Próstata/patología , Enfermedades de la Próstata/diagnóstico , Enfermedades de la Próstata/etiología , Enfermedades de la Próstata/fisiopatologíaAsunto(s)
Hipertensión/etiología , Hipertrigliceridemia/etiología , Síndrome Metabólico/complicaciones , Enfermedades de la Próstata/etiología , Triglicéridos/sangre , Humanos , Hipertensión/sangre , Hipertensión/fisiopatología , Hipertrigliceridemia/sangre , Hipertrigliceridemia/fisiopatología , Masculino , Síndrome Metabólico/sangre , Síndrome Metabólico/fisiopatología , Tamaño de los Órganos , Enfermedades de la Próstata/sangre , Enfermedades de la Próstata/fisiopatología , Factores de Riesgo , Conducta de Reducción del RiesgoRESUMEN
INTRODUCTION: Despite the global increase in awareness of prostatic diseases resulting from widespread availability of screening tools, there is no evidence that the knowledge, attitudes and screening practices of Nigerian men have improved regarding prostatic diseases. METHODS: A descriptive cross-sectional study amongst 305 community-dwelling men. Respondents were selected using multi-staged sampling techniques. Knowledge, attitudes and screening practices were determined based on responses to a semi-structured KAP questionnaire. Data were analyzed using SPSS version 18. Pearson's chi-square and Fisher's exact test (two-tail) with level of significance set at 0.05 were used to determine the level of statistical significance. Pearson's correlation coefficient was used to establish correlation between variables. RESULTS: Mean age of respondents was 63.4±11.8 years. Slightly less than half, 145(47.5%) were aware of prostate cancer (PCa) while only 99(32.5%) and 91(29.8%) were aware of BPH and prostatitis respectively. About a quarter (25.1%) had heard of PSA. The main sources of information were radio and television. Overall, 143(46.9%) respondents had good knowledge while 162(53.1%) had poor knowledge. Sexually transmitted disease was the commonest misconception as the cause of prostatic diseases. Overall, 44.3% had good attitudes. Only 31(10.2%) respondents had ever carried out screening for PCa. Only educational and occupational status had significant associations with level of knowledge and attitudes of participants. The only factor that influenced screening practices was educational status. CONCLUSION: There is a poor level of knowledge, attitudes and screening practices regarding prostatic diseases in Nigeria. We recommend a widespread public health education to improve knowledge, attitudes and screening practices for prostatic diseases.
Asunto(s)
Conocimientos, Actitudes y Práctica en Salud , Tamizaje Masivo/estadística & datos numéricos , Enfermedades de la Próstata/fisiopatología , Adulto , Anciano , Anciano de 80 o más Años , Estudios Transversales , Humanos , Masculino , Persona de Mediana Edad , Nigeria , Enfermedades de la Próstata/diagnóstico , Enfermedades de la Próstata/etiología , Hiperplasia Prostática/diagnóstico , Hiperplasia Prostática/fisiopatología , Neoplasias de la Próstata/diagnóstico , Neoplasias de la Próstata/fisiopatología , Prostatitis/diagnóstico , Prostatitis/fisiopatología , Encuestas y CuestionariosRESUMEN
Estrogens have historically been associated with female reproduction, but work over the last two decades established that estrogens and their main nuclear receptors (ESR1 and ESR2) and G protein-coupled estrogen receptor (GPER) also regulate male reproductive and nonreproductive organs. 17ß-Estradiol (E2) is measureable in blood of men and males of other species, but in rete testis fluids, E2 reaches concentrations normally found only in females and in some species nanomolar concentrations of estrone sulfate are found in semen. Aromatase, which converts androgens to estrogens, is expressed in Leydig cells, seminiferous epithelium, and other male organs. Early studies showed E2 binding in numerous male tissues, and ESR1 and ESR2 each show unique distributions and actions in males. Exogenous estrogen treatment produced male reproductive pathologies in laboratory animals and men, especially during development, and studies with transgenic mice with compromised estrogen signaling demonstrated an E2 role in normal male physiology. Efferent ductules and epididymal functions are dependent on estrogen signaling through ESR1, whose loss impaired ion transport and water reabsorption, resulting in abnormal sperm. Loss of ESR1 or aromatase also produces effects on nonreproductive targets such as brain, adipose, skeletal muscle, bone, cardiovascular, and immune tissues. Expression of GPER is extensive in male tracts, suggesting a possible role for E2 signaling through this receptor in male reproduction. Recent evidence also indicates that membrane ESR1 has critical roles in male reproduction. Thus estrogens are important physiological regulators in males, and future studies may reveal additional roles for estrogen signaling in various target tissues.
Asunto(s)
Estrógenos/metabolismo , Genitales Masculinos/metabolismo , Receptores de Estrógenos/metabolismo , Reproducción , Animales , Aromatasa/genética , Aromatasa/metabolismo , Genitales Masculinos/patología , Genitales Masculinos/fisiopatología , Genotipo , Humanos , Masculino , Ratones Noqueados , Mutación , Fenotipo , Próstata/metabolismo , Próstata/patología , Próstata/fisiopatología , Enfermedades de la Próstata/metabolismo , Enfermedades de la Próstata/patología , Enfermedades de la Próstata/fisiopatología , Receptores de Estrógenos/deficiencia , Receptores de Estrógenos/genética , Transducción de SeñalRESUMEN
BACKGROUND: Obesity is associated with increased risk of a number of serious medical conditions, including urological disorders. This study investigated the effect of lipidic extracts of saladette tomato pomace (STP) and Serenoa repens (SR) on the prostate and bladder in a rat obese model induced by high-carbohydrate diet. RESULTS: High-sucrose-fed rats showed higher prostate weight as well as increased contractility and stromal and epithelial hyperplasia in the prostate. Treatment with STP and SR improved contractility and diminished hyperplasia and hypertrophy in the prostate. Obese animals also showed impaired bladder contractility, but neither extract reversed this deterioration. In the histological study, a disarray in the process of smooth muscle cell proliferation with non-parallel fibers was observed; interestingly, treatment with STP and SR led to improvement in this derangement. CONCLUSION: These findings indicated impaired contractility and hyperplasia in the prostate and bladder of obese rats induced by high sucrose. STP and SR could enhance prostate function by reducing contractility and hyperplasia and improve smooth muscle fiber structure and decrease cell proliferation in the bladder, suggesting their possible health-beneficial effects on lower urinary tract symptoms. © 2017 Society of Chemical Industry.
Asunto(s)
Obesidad/complicaciones , Extractos Vegetales/administración & dosificación , Próstata/efectos de los fármacos , Serenoa/química , Solanum lycopersicum/química , Vejiga Urinaria/efectos de los fármacos , Animales , Humanos , Masculino , Obesidad/metabolismo , Próstata/fisiopatología , Enfermedades de la Próstata/tratamiento farmacológico , Enfermedades de la Próstata/etiología , Enfermedades de la Próstata/metabolismo , Enfermedades de la Próstata/fisiopatología , Ratas , Ratas Wistar , Vejiga Urinaria/fisiopatología , Enfermedades de la Vejiga Urinaria/tratamiento farmacológico , Enfermedades de la Vejiga Urinaria/etiología , Enfermedades de la Vejiga Urinaria/metabolismo , Enfermedades de la Vejiga Urinaria/fisiopatologíaRESUMEN
ABSTRACT Objectives To study the usefulness of MRI in preoperative evaluation of PFUDD. Can MRI provide additional information on urethral distraction defect (UDD) and cause of erectile dysfunction (ED)? Materials and Methods In this prospective study, consecutive male patients presenting with PFUDD were included from Feb 2011 till Dec 2012. Those with traumatic spinal cord injury and pre-existing ED were excluded. Patients were assessed using IIEF questionnaire, retrograde urethrogram and micturating cystourethrogram (RGU+MCU) and MRI pelvis. Primary end point was erectile function and secondary end point was surgical outcome. Results Twenty patients were included in this study. Fourteen patients (70%) were ≤40years; fifteen patients (75%) had ED, seven patients (35%) had severe ED. MRI findings associated with ED were longer median UDD (23mm vs. 15mm, p=0.07), cavernosal injury (100%, p=0.53), rectal injury (100%, p=0.53), retropubic scarring (60%, p=0.62) and prostatic displacement (60%, p=0.99). Twelve patients (60%) had a good surgical outcome, five (25%) had an acceptable outcome, three (15%) had a poor outcome. Poor surgical outcome was associated with rectal injury (66.7%, p=0.08), cavernosal injury (25%, p=0.19), retropubic scarring (18.1%, p=0.99) and prostatic displacement (16.7%, p=0.99). Five patients with normal erections had good surgical outcome. Three patients with ED had poor outcome (20%, p=0.20). Conclusions MRI did not offer significant advantage over MCU in the subgroup of men with normal erections. Cavernosal injury noted on MRI strongly correlated with ED. Role of MRI may be limited to the subgroup with ED or an inconclusive MCU.
Asunto(s)
Humanos , Masculino , Adolescente , Adulto , Adulto Joven , Pelvis/lesiones , Pelvis/diagnóstico por imagen , Uretra/lesiones , Uretra/diagnóstico por imagen , Enfermedades Uretrales/diagnóstico por imagen , Imagen por Resonancia Magnética/métodos , Disfunción Eréctil/diagnóstico por imagen , Pelvis/cirugía , Enfermedades de la Próstata/fisiopatología , Enfermedades de la Próstata/diagnóstico por imagen , Uretra/cirugía , Uretra/fisiopatología , Enfermedades Uretrales/cirugía , Enfermedades Uretrales/fisiopatología , Micción/fisiología , Radiografía , Proyectos Piloto , Estudios Prospectivos , Encuestas y Cuestionarios , Reproducibilidad de los Resultados , Resultado del Tratamiento , Estadísticas no Paramétricas , Periodo Preoperatorio , Disfunción Eréctil/etiología , Disfunción Eréctil/fisiopatología , Persona de Mediana EdadRESUMEN
OBJECTIVES: To study the usefulness of MRI in preoperative evaluation of PFUDD. Can MRI provide additional information on urethral distraction defect (UDD) and cause of erectile dysfunction (ED)? MATERIALS AND METHODS: In this prospective study, consecutive male patients presenting with PFUDD were included from Feb 2011 till Dec 2012. Those with traumatic spinal cord injury and pre-existing ED were excluded. Patients were assessed using IIEF questionnaire, retrograde urethrogram and micturating cystourethrogram (RGU+MCU) and MRI pelvis. Primary end point was erectile function and secondary end point was surgical outcome. RESULTS: Twenty patients were included in this study. Fourteen patients (70%) were ≤40years; fifteen patients (75%) had ED, seven patients (35%) had severe ED. MRI findings associated with ED were longer median UDD (23mm vs. 15mm, p=0.07), cavernosal injury (100%, p=0.53), rectal injury (100%, p=0.53), retropubic scarring (60%, p=0.62) and prostatic displacement (60%, p=0.99). Twelve patients (60%) had a good surgical outcome, five (25%) had an acceptable outcome, three (15%) had a poor outcome. Poor surgical outcome was associated with rectal injury (66.7%, p=0.08), cavernosal injury (25%, p=0.19), retropubic scarring (18.1%, p=0.99) and prostatic displacement (16.7%, p=0.99). Five patients with normal erections had good surgical outcome. Three patients with ED had poor outcome (20%, p=0.20). CONCLUSIONS: MRI did not offer significant advantage over MCU in the subgroup of men with normal erections. Cavernosal injury noted on MRI strongly correlated with ED. Role of MRI may be limited to the subgroup with ED or an inconclusive MCU.
Asunto(s)
Disfunción Eréctil/diagnóstico por imagen , Imagen por Resonancia Magnética/métodos , Pelvis/diagnóstico por imagen , Pelvis/lesiones , Uretra/diagnóstico por imagen , Uretra/lesiones , Enfermedades Uretrales/diagnóstico por imagen , Adolescente , Adulto , Disfunción Eréctil/etiología , Disfunción Eréctil/fisiopatología , Humanos , Masculino , Persona de Mediana Edad , Pelvis/cirugía , Proyectos Piloto , Periodo Preoperatorio , Estudios Prospectivos , Enfermedades de la Próstata/diagnóstico por imagen , Enfermedades de la Próstata/fisiopatología , Radiografía , Reproducibilidad de los Resultados , Estadísticas no Paramétricas , Encuestas y Cuestionarios , Resultado del Tratamiento , Uretra/fisiopatología , Uretra/cirugía , Enfermedades Uretrales/fisiopatología , Enfermedades Uretrales/cirugía , Micción/fisiología , Adulto JovenRESUMEN
Prostatic calculi are a common finding on transrectal prostate ultrasound. However, it remains unclear whether they are significantly associated with lower urinary tract symptoms (LUTS). Our objective was to evaluate the association between prostatic calculi and LUTS with a focus on "calculi burden" because no studies have investigated prostatic calculi using "calculi burden" as an indicator. A total of 606 participants who received transrectal prostate ultrasound were divided into two groups according to the presence of prostatic calculi. "Calculi burden" was defined as the sum of the transverse diameters of all visible calculi within the prostate. The International Prostatic Symptom Score (IPSS) and a quality of life (QoL) score were collected. Both groups were compared, and a multivariate analysis was performed to predict moderate/severe LUTS. Linear correlation was evaluated between calculi burden and IPSS in the calculi group. No differences in total IPSS, voiding IPSS, or QoL score were detected between the two groups, but storage IPSS was significantly higher in the calculi group than that of controls. The multivariate analysis showed that the presence of prostatic calculi was not an independent predictor of moderate/severe LUTS. A positive linear correlation was detected between calculi burden and storage IPSS in calculi group (r = 0.148). However, no correlation was found between calculi burden and total IPSS, voiding IPSS, or QoL score. Our results showed that the presence of prostatic calculi was not a significant factor predicting moderate/severe LUTS. However, an increased calculi burden may be associated with aggravating storage symptoms.
Asunto(s)
Cálculos/fisiopatología , Enfermedades de la Próstata/fisiopatología , Adulto , Anciano , Cálculos/psicología , Cálculos/terapia , Costo de Enfermedad , Humanos , Síntomas del Sistema Urinario Inferior/fisiopatología , Masculino , Persona de Mediana Edad , Enfermedades de la Próstata/psicología , Enfermedades de la Próstata/terapia , Calidad de Vida , Ultrasonido , MicciónRESUMEN
No disponible
Asunto(s)
Humanos , Masculino , Persona de Mediana Edad , Enfermedades Urológicas/complicaciones , Enfermedades Urológicas/diagnóstico , Enfermedades Urológicas/fisiopatología , Síndrome Metabólico/complicaciones , Síndrome Metabólico/tratamiento farmacológico , Enfermedades Urológicas/tratamiento farmacológico , Estudios Retrospectivos , Próstata/patología , Enfermedades de la Próstata/complicaciones , Enfermedades de la Próstata/diagnóstico , Enfermedades de la Próstata/fisiopatologíaRESUMEN
The article presents the results of a multi-center observational study carried out in 2014-2015 comprising 630 male patients from 23 Russian health care institutions. The study aimed to accumulate epidemiological data on sexual dysfunction in men and test the efficacy and safety of biologically active complex NeyroDoz. Data for the study were collected using questionnaires. The study findings showed a high prevalence of premature ejaculation (PE) in 38.2% of patients with chronic prostatitis (CP) and in 33.25% of patients with erectile dysfunction (ED). The data were analyzed for the total study population (n=630) and separately for three groups of patients selected according to the presence of PE (n=582), orgasmic disorders without PE (n=17) and increased anxiety related to urological diseases without PE (n=31). In all patients of the study, NeyroDoz intake produced a statistically significant increase in the intensity of orgasm from 5,0+/-2,2 to 7,6+/-1,8 points, duration of sexual intercourse from 3,3+/-5,4 to 6,5+/-4,8 min, and satisfaction with sexual intercourse from 1,4+/-0,7 to 3,1+/-1,1 points. In 81% of PE patients the duration of penetration phase of sexual intercourse increased by 50% of the baseline values. The intensity of orgasm increased on average by 60% and 75% in men with PE and orgasm disorders without PE, respectively. Reduction of psycho-emotional burden was observed in 90% of patients with anxiety and depression. The dietary supplement NeyroDoz showed clinical efficacy and safety in the combined treatment of sexual dysfunction in men.
Asunto(s)
Suplementos Dietéticos , Disfunción Eréctil/tratamiento farmacológico , Eyaculación Prematura/tratamiento farmacológico , Enfermedades de la Próstata/tratamiento farmacológico , Adulto , Anciano , Disfunción Eréctil/fisiopatología , Disfunción Eréctil/psicología , Humanos , Masculino , Persona de Mediana Edad , Eyaculación Prematura/fisiopatología , Eyaculación Prematura/psicología , Enfermedades de la Próstata/fisiopatología , Enfermedades de la Próstata/psicologíaRESUMEN
OBJECTIVE: To study the relation between uroflow Stop Test and early recovery of potency following robot-assisted radical prostatectomy (RARP). We recently showed that the ability to completely stop urine flow during voiding, measured objectively by uroflowmetry at the time of catheter removal (uroflow Stop Test) can predict early urinary continence recovery following RARP. MATERIALS AND METHODS: In this prospective observational cohort, data were collected on 108 patients operated by a single surgeon (AEH). Eighty patients had a positive uroflow Stop Test (group one) and 28 had a negative Stop Test (group two). Patients were followed for a minimum of 2 years. Covariates included age, body mass index, international prostate symptom score and sexual health inventory for men scores, prostate-specific antigen, tumor stage, prostate volume, nerve sparing status, and estimated blood loss. RESULTS: Preoperative characteristics were comparable between both groups except nerve sparing and prostate-specific antigen which were statistically higher in group one (P <.05). Early 3- and 6-months recovery of erectile function was significantly higher in group one. Potency rates in group one and two at 1, 3, 6, 9, 12, 18, and 24 months were 25% vs 14.3% (P = .241), 54.5% vs 18.5% (P = .001), 55.4% vs 18.5% (P = .001), 56.4% vs 36% (P = .084), 66.6% vs 50% (P = .141), 65.5% vs 56% (P = .404) and 73.2% vs 57.7% (P = .160) respectively. Uroflow Stop Test was independent predictor of early potency recovery on multivariate regression analysis at 6 months [odds ratio 6.042 (confidence interval 95% 1.496-24.413) P = .012]. CONCLUSION: Uroflow Stop Test is simple and can help predict early potency recovery following RARP.
Asunto(s)
Disfunción Eréctil/rehabilitación , Diafragma Pélvico/fisiopatología , Erección Peniana/fisiología , Prostatectomía/métodos , Enfermedades de la Próstata/cirugía , Robótica , Micción/fisiología , Anciano , Disfunción Eréctil/etiología , Disfunción Eréctil/fisiopatología , Humanos , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Enfermedades de la Próstata/complicaciones , Enfermedades de la Próstata/fisiopatología , Recuperación de la Función/fisiología , Resultado del TratamientoRESUMEN
The article presents the experience of use of the new superselective alpha-blocker urorec (silodosin) in the treatment of 30 patients with lower urinary tract symptoms aged 49 to 69 years. Patients have received silodosin 1 capsule a day for 2 months. According to the results of study, silodosin has demonstrated high efficacy and an acceptable safety profile. It was shown that silodosin does not increase the risk of hypotension in patients taking antihypertensive medications. Therapy with silodosin had positive and statistically significant impact on subjective and objective symptoms of the disease, which was confirmed by the IPSS-QoL score and uroflowmetry. Silodosin has rapid onset of effect (3-4 days after the start of treatment); it can be used in all patients suffering from BPH and having indications to the administration of alpha-blockers, and does not require correction of doses of antihypertensive drugs in the case of combined appointment.
Asunto(s)
Antagonistas de Receptores Adrenérgicos alfa 1/administración & dosificación , Indoles/administración & dosificación , Enfermedades de la Próstata/tratamiento farmacológico , Antagonistas de Receptores Adrenérgicos alfa 1/efectos adversos , Anciano , Humanos , Indoles/efectos adversos , Masculino , Persona de Mediana Edad , Enfermedades de la Próstata/patología , Enfermedades de la Próstata/fisiopatologíaRESUMEN
BACKGROUND: A visual prostate symptom score (VPSS) using pictograms was developed to assess the force of the urinary stream, urinary frequency, nocturia and quality of life (QoL). OBJECTIVE: To compare the VPSS with the international prostate symptom score (IPSS) and maximum (Qmax) and average (Qave) urinary flow rates in men from diverse language groups with limited schooling. METHODS: Men with lower urinary tract symptoms admitted to the urology ward at Windhoek Central Hospital, Namibia, were evaluated. Patients who were unable to complete the questionnaires alone were assisted by a doctor or nurse. Local ethics committee approval was obtained. Statistical analysis was performed using Student's t-test and Spearman's rank correlation test. RESULTS: One hundred men (mean age 56.3 years, range 20.1 - 95.4) were evaluated over a period of one year. All the men understood one or more of 15 languages, and 30 were illiterate; 32 had <5 years of schooling, 34 had 5 - 9 years and 34 had >9 years. The VPSS took significantly less time to complete than the IPSS. There were statistically significant correlations between the total VPSS and IPSS scores, between the four VPSS questions and the corresponding IPSS questions, and between Qmax and Qave and the VPSS total and VPSS questions on the force of the urinary stream and QoL. CONCLUSION: The VPSS pictograms depicting the force of the urinary stream and QoL correlated significantly with Qmax and Qave, indicating that they can be used as single-item questions to rapidly assess bladder outflow obstruction in men with limited education.
Asunto(s)
Enfermedades de la Próstata/diagnóstico , Enfermedades de la Próstata/fisiopatología , Evaluación de Síntomas/métodos , Micción/fisiología , Escala Visual Analógica , Adulto , Anciano , Anciano de 80 o más Años , Escolaridad , Humanos , Internacionalidad , Lenguaje , Masculino , Persona de Mediana Edad , Namibia , Calidad de Vida , Adulto JovenRESUMEN
A growing body of literature has established the anabolic benefi ts of testosterone (T) therapy in hypogonadal men. However, there remains a paucity of data regarding the risks of exogenous androgen use in older men and the potential for adverse effects on the prostate gland. Whether T therapy in older, hypogonadal men might worsen lower urinary tract symptoms or exacerbate, unmask, or even incite prostate cancer development has tempered enthusiasm for T therapy, while known prostatic disease has served as a relative contraindication to T therapy. Androgens are necessary for the development and maintenance of the prostate gland. However, epidemiologic studies do not consistently fi nd a positive relationship between endogenous serum androgen concentrations and the risk of prostate disease. Recent data demonstrate that 5α-reductase inhibitors decrease the risk of low-grade prostate cancer, suggesting that modifying androgen metabolism may have beneficial effects on prostate health, yet similar reductions in high-grade disease have not been observed, thereby questioning the true clinical benefits of these agents for chemoprevention. Knowing how to best investigate the relationship between androgens and the development of prostate disease given the lack of large, randomized trials is difficult. Accumulating data challenges the assumption that alterations in serum androgens have parallel effects within the prostate hormonal environment or change androgen-regulated processes within the gland. Long-term intervention studies are needed to truly ascertain the effects of androgen manipulation on prostate tissue and disease risk. However, available data do not support the notion that restoring serum androgens to normal physiologic ranges drives prostate disease.
Asunto(s)
Andrógenos/fisiología , Enfermedades de la Próstata/fisiopatología , Neoplasias de la Próstata/fisiopatología , Humanos , MasculinoRESUMEN
INTRODUCTION: Published data suggest that patients with acromegaly have an increased prevalence of prostate disorders. OBJECTIVE: To evaluate prostatic disorders in acromegalic patients comparing these results after one year of treatment of acromegaly and with a group of healthy men. MATERIALS AND METHODS: This study was composed of two parts: sectional study comparing patients with healthy controls (baseline) and prospective, longitudinal study (at baseline and after one year of treatment). Forty acromegalic patients were enrolled and evaluated at baseline and after one year with the application of international prostatic symptoms score (IPSS), digital rectal examination, measurements of growth hormone (GH), insulin-like growth factor-I (IGF-I), insulin-like growth factor-binding protein-3 (IGFBP-3), sex hormone-binding globulin (SHBG), prolactin, luteinizing hormone (LH), follicle-stimulating hormone (FSH), total testosterone, total and free prostate-specific antigen (PSA) levels and prostate ultrasonography (US). Thirty healthy men were selected as control group. RESULTS: We stratified patients and controls according to age, considering 40 years-old as cut off. Healthy controls under 40 had IPSS values lower than acromegalic patients. When considering only older patients and controls prostate hyperplasia and structural abnormalities were more frequent in acromegalics. After one year of treatment there was significant decrease in GH, IGF-I and prostate volume in acromegalics over 40 years-old. CONCLUSIONS: Acromegalics under 40 have more urinary symptoms according to IPSS and above 40 years-old higher frequency of structural changes and increased prostate volume than healthy men. Significant reduction of GH and IGF-I levels during treatment of acromegaly leads to decrease in the prostate volume.
Asunto(s)
Acromegalia/fisiopatología , Acromegalia/terapia , Enfermedades de la Próstata/fisiopatología , Acromegalia/metabolismo , Adulto , Factores de Edad , Anciano , Brasil , Estudios de Casos y Controles , Tacto Rectal , Gonadotropinas Hipofisarias/sangre , Hormona del Crecimiento/sangre , Humanos , Proteína 3 de Unión a Factor de Crecimiento Similar a la Insulina/sangre , Factor I del Crecimiento Similar a la Insulina/análisis , Masculino , Persona de Mediana Edad , Antígeno Prostático Específico/sangre , Enfermedades de la Próstata/metabolismo , Globulina de Unión a Hormona Sexual/análisis , Testosterona/sangre , Resultado del TratamientoRESUMEN
Introduction Published data suggest that patients with acromegaly have an increased prevalence of prostate disorders. Objective To evaluate prostatic disorders in acromegalic patients comparing these results after one year of treatment of acromegaly and with a group of healthy men. Materials and Methods This study was composed of two parts: sectional study comparing patients with healthy controls (baseline) and prospective, longitudinal study (at baseline and after one year of treatment). Forty acromegalic patients were enrolled and evaluated at baseline and after one year with the application of international prostatic symptoms score (IPSS), digital rectal examination, measurements of growth hormone (GH), insulin-like growth factor-I (IGF-I), insulin-like growth factor-binding protein-3 (IGFBP-3), sex hormone-binding globulin (SHBG), prolactin, luteinizing hormone (LH), follicle-stimulating hormone (FSH), total testosterone, total and free prostate-specific antigen (PSA) levels and prostate ultrasonography (US). Thirty healthy men were selected as control group. Results We stratified patients and controls according to age, considering 40 years-old as cut off. Healthy controls under 40 had IPSS values lower than acromegalic patients. When considering only older patients and controls prostate hyperplasia and structural abnormalities were more frequent in acromegalics. After one year of treatment there was significant decrease in GH, IGF-I and prostate volume in acromegalics over 40 years-old. Conclusions Acromegalics under 40 have more urinary symptoms according to IPSS and above 40 years-old higher frequency of structural changes and increased prostate volume than healthy men. Significant reduction of GH and IGF-I levels during treatment of acromegaly leads to decrease in the prostate volume. .
Asunto(s)
Adulto , Anciano , Humanos , Masculino , Persona de Mediana Edad , Acromegalia/fisiopatología , Acromegalia/terapia , Enfermedades de la Próstata/fisiopatología , Factores de Edad , Acromegalia/metabolismo , Brasil , Estudios de Casos y Controles , Tacto Rectal , Gonadotropinas Hipofisarias/sangre , Hormona del Crecimiento/sangre , /sangre , Factor I del Crecimiento Similar a la Insulina/análisis , Antígeno Prostático Específico/sangre , Enfermedades de la Próstata/metabolismo , Globulina de Unión a Hormona Sexual/análisis , Resultado del Tratamiento , Testosterona/sangreRESUMEN
OBJECTIVE: To investigate the correlation between prostatic calcification and lower urinary tract symptoms (LUTS) in a sample of middle-aged men receiving health checkups. METHODS: Subjects aged 40 years or older who voluntarily underwent transrectal prostate ultrasound (TRUS) and fulfilled International Prostate Symptoms Score (IPSS) as part of their medical checkup were enrolled in this study. The prostatic calcification grading and prostate volume (PV) were measured by TRUS. The medical history, demographics, and metabolic markers were also evaluated. Logistic regression was used to analyze the correlation between prostatic calcification and LUTS. RESULTS: A total of 604 men were enrolled as study subjects. The prostatic calcification grading was significantly associated with age and PV instead of metabolic markers. Compared to the nonprostatic calcification group, the moderate/marked prostatic calcification group had a significantly higher age-adjusted IPSS (8.69 vs 6.87, P <.01), quality of life (QOL) score (2.57 vs 2.17, P <.01), storage score (3.74 vs 3.06, P = .01), voiding score (4.95 vs 3.72, P <.01), and more maximum flow rate <15 mL/sec (40.4% vs 24.5%, P <.01). Prostatic calcification grading was positively correlated with age-adjusted IPSS, QOL, voiding, and storage scores (all P for trend <.05). Further multivariate analysis indicated that moderate/marked prostatic calcification was an independent risk factors for moderate to severe LUTS (odds ratio [OR] = 1.68, P = .02). CONCLUSION: Prostatic calcification worsened IPSS, QOL, storage, voiding symptoms, and maximum urine flow (Qmax) in middle-aged men receiving a health checkup. Moderate/marked prostatic calcification was an independent risk factor for moderate to severe LUTS.